An interventional study of anodal tDCS and cathodal tDCS in Motor Activity and Motor Neuroplasticity, sponsored by University of North Carolina, Chapel Hill. Completed at 1 site in United States. Open to male participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-04.
Sponsored by University of North Carolina, Chapel Hill · Not applicable, Interventional, and Basic science
Among 35 studies in Motor Activity by University of North Carolina, Chapel Hill — 4 open to participants now, 4 under way, none of them phase 3. Motor Activity · University of North Carolina, Chapel Hill.
Among the 35 studies in Motor Activity by University of North Carolina, Chapel Hill, this one is the 31st largest by enrollment, is one of 2 that started in 2018, is one of 34 with no phase, and was the 21st registered.
9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.
Browse Motor Activity studies →4 of the 35 studies in Motor Activity by University of North Carolina, Chapel Hill are open now, in 1 country. Recruiting first, the newest first:
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–99 · Healthy volunteers
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+ · Healthy volunteers
University of North Carolina, Chapel Hill · Sites in United States
Ages 18–45 · Women only
University of North Carolina, Chapel Hill · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 1,201 Motor Activity studies recruiting now, 517 (43%) set no upper age limit and 535 (45%) stop at 75 or younger; 180 take children under 18; 420 take healthy volunteers.
This study: 18 Years to 35 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2018.
This study's enrollment of 19 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.
Median enrollment 78 across the 35 interventional studies. Of the 31 that completed or were terminated, 8 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of North Carolina, Chapel Hill is the lead sponsor of 1,372 studies on the registry; 133 are open to participants now.
Of its 161 completed or terminated interventional studies of FDA-regulated products, 139 (86%) have results posted.
2 of the studies in Motor Activity by University of North Carolina, Chapel Hill that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07699302University of North Carolina, Chapel HillClearance in Primary Ciliary Dyskinesia | 2027-01 |
| NCT07795853University of North Carolina, Chapel HillCreatine for Recovery and Thinking in Mothers | 2027-05-10 |
Among the 35 studies in Motor Activity by University of North Carolina, Chapel Hill, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Investigating modulation of motor cortex excitability by transcranial magnetic stimulation and transcranial direct current stimulation.
Purpose of this pilot study is to modulate the motor cortex excitability by transcranial magnetic stimulation and transcranial direct current stimulation. Electromyography will be recorded on right abductor digiti minimi muscle to find the motor threshold and measure motor evoked potentials for each healthy participant. In addition, electroencephalography (EEG) data will be collected on the scalp with a high-density EEG net. Eighteen healthy participants will be in this study. Each participant will be seated in a reclining chair and applied non-invasive magnetic and electrical stimulations on the scalp. At baseline, the participant's resting motor threshold (RMT) will be estimated by adjusting the intensity of TMS applied on the left motor cortex to achieve motor-evoked potentials of about 50 uV with 10 TMS pulses at a rate of 0.25 Hz. Then a 3-condition, 3-session, 6-sequence randomized crossover experiment will be used to characterize and compare three versions of tDCS stimulation: anode, cathode, sham. Before and after a 10-min tDCS condition is applied, TMS pulses at 120% of RMT intensity will be applied for 10 minutes and TMS-evoked potential and motor-evoked potential amplitudes will be measured. Each session has at least 1-day gap to remove outlasting effects. We will also be collecting structural magnetic resonance imaging (sMRI) to target primary motor cortex precisely.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neurological disorders and conditions, including, but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This anodal tDCS on the left motor cortex will be stimulated with 2mA for 10 minutes.
Device: anodal tDCS
Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). This cathodal tDCS on the left motor cortex will be stimulated with -2mA for 10 minutes.
Device: cathodal tDCS
Two electrodes will be applied to the scalp (one on the left motor cortex, one on the right supraorbital cortex). Sham stimulation with 2mA for 40 seconds will be applied.
Device: sham tDCS
The participant will receive anodal tDCS with 2 mA for 10 minutes on the left motor cortex.
The participant will receive cathodal tDCS with -2 mA for 10 minutes on the left motor cortex.
The participant will receive sham tDCS with 2 mA for 40 seconds on the left motor cortex which mimics the skin sensations as active tDCS interventions.
Changes in Motor-evoked Potentials Ratios
The investigators will record motor-evoked potentials and calculate changes in between before and after 2mA tDCS stimulation for 10 minutes.
Time frame: right before and after 2mA tDCS stimulation for 10 minutes at each session
Changes in TMS-evoked Potentials Ratios
The investigators will record TMS-evoked potentials using EEG and calculate changes in between before and after 2mA tDCS stimulation for 10 minutes.
Time frame: right before and after 2mA tDCS stimulation for 10 minutes at each session
Changes in Resting-state EEG Dynamics Ratios
The investigators will record participants' resting state for 4 minutes using EEG (2 minutes for eyes-closed and 2 minutes for eyes-open)
Time frame: 4 minutes recordings before and after each 2mA tDCS stimulation for 10 minutes at each session
| Milestone | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 3 |
| Completed | 4 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode |
|---|---|---|---|---|---|---|
| Started | 4 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode |
|---|---|---|---|---|---|---|
| Started | 3 | 3 | 3 | 3 | 3 | 3 |
| Completed | 3 | 3 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
The investigators will record motor-evoked potentials and calculate changes in between before and after 2mA tDCS stimulation for 10 minutes.
| Ratio (unit: uV) | Anodal tDCS | Cathodal tDCS | Sham tDCS |
|---|---|---|---|
| Changes in Motor-evoked Potentials Ratios | 1.32 ± 0.09 | 0.73 ± 0.07 | 1.03 ± 0.05 |
The investigators will record TMS-evoked potentials using EEG and calculate changes in between before and after 2mA tDCS stimulation for 10 minutes.
| Ratio (unit: uV) | Anodal tDCS | Cathodal tDCS | Sham tDCS |
|---|---|---|---|
| Changes in TMS-evoked Potentials Ratios | 1.5 ± 0.5 | 0.8 ± 0.4 | 1.1 ± 0.4 |
The investigators will record participants' resting state for 4 minutes using EEG (2 minutes for eyes-closed and 2 minutes for eyes-open)
| Ratio (unit: uV) | Anodal tDCS | Cathodal tDCS | Sham tDCS |
|---|---|---|---|
| Changes in Resting-state EEG Dynamics Ratios | 1.2 ± 0.7 | 0.8 ± 0.3 | 1.1 ± 0.5 |
Collected over After the study session on each day, an intervention was given, approximately 2 hours. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Anodal tDCS | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Cathodal tDCS | 0/18 (0%) | 0/18 (0%) | 0/18 (0%) |
| Sham tDCS | 0/18 (0%) | 0/18 (0%) | 0/18 (0%) |
One participant signed the consent form and provided baseline characteristics but research data collection for this participant was not performed.
| Age, Categorical(Participants) | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 3 | 3 | 3 | 3 | 3 | 19 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode | Total |
|---|---|---|---|---|---|---|---|
| Mean | 28.75 ± 6.68 | 25.33 ± 6.94 | 22.33 ± 1.24 | 20.66 ± 0.47 | 22 ± 4.24 | 25.33 ± 6.12 | 24.31 ± 5.84 |
| Sex: Female, Male(Participants) | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode | Total |
|---|---|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Male | 4 | 3 | 3 | 3 | 3 | 3 | 19 |
| Race (NIH/OMB)(Participants) | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 | 2 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 2 | 1 | 0 | 4 |
| White | 2 | 2 | 1 | 1 | 1 | 1 | 8 |
| More than one race | 1 | 1 | 1 | 0 | 0 | 0 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Anode -> Cathode -> Sham | Anode -> Sham -> Cathode | Cathode -> Anode -> Sham | Cathode -> Sham -> Anode | Sham -> Anode -> Cathode | Sham -> Cathode -> Anode | Total |
|---|---|---|---|---|---|---|---|
| United States | 4 | 3 | 3 | 3 | 3 | 3 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2018 to primary completion in Jan 2019, 5 months.
Results were first posted in Oct 2019, 8 months after primary completion.
Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's 5 months is below that.
Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of North Carolina, Chapel Hill →